Title
Category
Credits
Event date
Cost
Updates in the Management of Biliary Tract Cancers
  • Hepatobiliary Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The advent of novel targeted agents has led to a shift in the treatment paradigm of advanced biliary tract cancers. In recent years, multiple targeted agents were FDA-approved, including tumor-agnostic agents. As such, molecular profiling has become increasingly useful and can potentially help guide treatment decisions.